MiMedx Group MDXG Allowance for Doubtful Accounts Receivable (Current)

Allowance for Doubtful Accounts Receivable (Current) at other companies

IAR

Integra LifeSciencesIART

$7.33M+6.9%

SANUWAVE Health, Inc.SNWV

$1.62M+26.5%

SolventumSOLV

$82M-5.7%

InfuSystem HoldingsINFU

$300K—

Sanara MedTech Inc.SMTI

$1.51M+30.8%

EnovisENOV

$28.18M0.0%

FAQ

What is MiMedx Group's allowance for doubtful accounts receivable (current)?

MiMedx Group (MDXG) reported allowance for doubtful accounts receivable (current) of $14.8M in Q2 2026.

How has MiMedx Group's allowance for doubtful accounts receivable (current) changed year-over-year?

MiMedx Group's allowance for doubtful accounts receivable (current) increased by 275.3% year-over-year, from $3.94M to $14.8M.

What is the long-term trend for MiMedx Group's allowance for doubtful accounts receivable (current)?

Over 5 years (2020 to 2025), MiMedx Group's allowance for doubtful accounts receivable (current) has grown at a 63.8% compound annual growth rate (CAGR), from $737K to $8.7M.

What does allowance for doubtful accounts receivable (current) mean?

This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.